127 related articles for article (PubMed ID: 16861219)
21. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
22. The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice.
Wang Y; Zhang L; Wu X; Gurley EC; Kennedy E; Hylemon PB; Pandak WM; Sanyal AJ; Zhou H
Hepatology; 2013 Mar; 57(3):1005-16. PubMed ID: 23080229
[TBL] [Abstract][Full Text] [Related]
23. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
24. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.
Lagathu C; Eustace B; Prot M; Frantz D; Gu Y; Bastard JP; Maachi M; Azoulay S; Briggs M; Caron M; Capeau J
Antivir Ther; 2007; 12(4):489-500. PubMed ID: 17668557
[TBL] [Abstract][Full Text] [Related]
25. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Capel E; Auclair M; Caron-Debarle M; Capeau J
Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
[TBL] [Abstract][Full Text] [Related]
26. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X.
Roberts CK; Liang K; Barnard RJ; Kim CH; Vaziri ND
Kidney Int; 2004 Oct; 66(4):1503-11. PubMed ID: 15458444
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
28. Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice.
Helsley RN; Sui Y; Ai N; Park SH; Welsh WJ; Zhou C
Mol Pharmacol; 2013 Jun; 83(6):1190-9. PubMed ID: 23519392
[TBL] [Abstract][Full Text] [Related]
29. Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction.
Lei B; Zha W; Wang Y; Wen C; Studer EJ; Wang X; Jin F; Wang G; Zhang L; Zhou H
Mol Pharm; 2010 Jun; 7(3):844-53. PubMed ID: 20349948
[TBL] [Abstract][Full Text] [Related]
30. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
Liang K; Vaziri ND
Kidney Int; 2003 Jul; 64(1):192-8. PubMed ID: 12787409
[TBL] [Abstract][Full Text] [Related]
31. The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.
Mencarelli A; Cipriani S; Renga B; Francisci D; Palladino G; Distrutti E; Baldelli F; Fiorucci S
PLoS One; 2010 Oct; 5(10):e13238. PubMed ID: 20949026
[TBL] [Abstract][Full Text] [Related]
32. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
Xu A; Yin S; Wong L; Chan KW; Lam KS
Endocrinology; 2004 Feb; 145(2):487-94. PubMed ID: 14592951
[TBL] [Abstract][Full Text] [Related]
33. Polyphenol-rich black chokeberry (Aronia melanocarpa) extract regulates the expression of genes critical for intestinal cholesterol flux in Caco-2 cells.
Kim B; Park Y; Wegner CJ; Bolling BW; Lee J
J Nutr Biochem; 2013 Sep; 24(9):1564-70. PubMed ID: 23517916
[TBL] [Abstract][Full Text] [Related]
34. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
Wu X; Sun L; Zha W; Studer E; Gurley E; Chen L; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Wang G; Chen J; Wang JY; Zhou H
Gastroenterology; 2010 Jan; 138(1):197-209. PubMed ID: 19732776
[TBL] [Abstract][Full Text] [Related]
35. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
Sension M; Deckx H
AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
[TBL] [Abstract][Full Text] [Related]
36. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
37. Lipoprotein cholesterol uptake mediates up-regulation of bile-acid synthesis by increasing cholesterol 7alpha-hydroxylase but not sterol 27-hydroxylase gene expression in cultured rat hepatocytes.
Post SM; Twisk J; van der Fits L; de Wit EC; Hoekman MF; Mager WH; Princen HM
Biochem J; 1999 Jul; 341 ( Pt 2)(Pt 2):339-46. PubMed ID: 10393091
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
39. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Perez I; Gatell JM;
HIV Med; 2014 Jul; 15(6):330-8. PubMed ID: 24417772
[TBL] [Abstract][Full Text] [Related]
40. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
